Graham Ross Andrews
Professor Timothy Mason
Graham Ross Andrews
Executive Director
Dr Graham Ross Andrews is a corporate finance specialist with many years' experience working with global organisations, advising on global transactions.
He holds a MA in Mathematics from Oxford University and a PhD in Mathematics from Heriot-Watt University in Edinburgh.
Graham worked with BP Plc's Corporate Finance and Corporate Planning Divisions, and was a Director of Corporate Finance at Chase Manhattan Bank. He has also served as Managing Director of WI Carr, part of the wider Banque Indosuez Group.
More recently he has advised organisations with a focus in the oil, gas and mining industries worldwide, and most recently those in the renewable energy space.
Contact:
Paul McClory
Professor Timothy Mason
Graham Ross Andrews
Director & Chairman
Paul is an international businessman who has spent most of his career developing new environmental technologies to market take-off. He has business interests in Europe, North America and Africa and is mainly involved with small technology companies.
Paul was instrumental in the 1970’s of the founding of Airship Industries in London with Roger Munk - the relaunch of the modern airship industry. He was a co-founder of UK based Calorex Heat Pumps, now one of Europe’s biggest manufacturers of heat pumps.
In 2003 Paul patented a novel extraction method to recover high value proteins in oil seeds. This led to BioExx Specialty Proteins, which became a listed company on the Toronto Stock exchange with a market capitalisation of US$400m.
He then formed a company with Michael Dobell to develop Vernonia as a commercial oilseed crop in Ethiopia containing unique naturally epoxidised oils. They discovered and patented the use of Vernonia oil for the treatment of a number of skin diseases such as psoriasis.
Since 2015 he has been focused on steering the SonoChem technology to granted patent status in the United States and Europe – achieved in September 2019.
Contact:
Professor Timothy Mason
Professor Timothy Mason
Professor Timothy Mason
Chief Technology Officer
Tim is one of the two inventors of the SonoChem technology. An acknowledged author and world authority, Tim was one of the earliest proponents of Sonochemistry technology. He has over 40 years of experience in Sonochemistry, his latest contribution being as co-author of a two volume treatise on the subject, published by De Gruyter in 2023 – Vol. 1 Sonochemistry: Fundamentals and Evolution and Vol. 2 Sonochemistry: Applications and Developments. Tim describes Sonochemistry as ''the use of power ultrasound in many different applications of science and technology”, and explains why industry has become increasingly drawn to Sonochemistry because it provides a green and clean alternative to conventional technologies. Tim is a Fellow of the Royal Society of Chemistry, served for 23 years as the first president of the European Society of Sonochemistry and is the recently retired Editor in Chief of Ultrasonics Sonochemistry.
Neil Speakman
Dr F. John Mills
Professor Timothy Mason
Advisor
Neil has a strong international background in investment banking, corporate advice and capital raising and spends his time between Hong Kong, Shanghai, New York, London and Perth.
He has established, funded and advised a number of emerging technology companies and maintains very strong connections worldwide.
After graduating B.Com at University of Melbourne, Neil qualified as a Chartered Accountant with PwC before joining Morgan Grenfell in London and then Ord Minett in Hong Kong. He subsequently founded and managed a successful accountancy practice in Hong Kong, with worldwide clientele.
Neil then founded Advanced Material Resources Limited (AMR) in conjunction with the State Council Rare Earth Office, China National Nuclear Corporation and other State owned corporations. AMR became Neo Material Technologies, a leading rare earth company.
Contact:
Dr F. John Mills
Dr F. John Mills
Dr F. John Mills
Advisor
John Mills is an accomplished medical executive and entrepreneur with a background in general management of contract research organizations and pharmaceutical development.
Dr. Mills received his M.D. from Cambridge University and his Ph.D. in endocrinology from Surrey University in the United Kingdom. He holds diplomas in pharmaceutical medicine, aviation medicine and marketing and has authored more than 40 scientific papers as well as a textbook on aviation medicine.
He is an experienced leader of teams in culturally diverse environments, having lived & worked in the US, Europe and Asia. He has been a successful leader of profit centres over twenty five years, with a track record of growing revenues, profitability and market share.